Audience Questions on Selecting Optimal Therapy for mBC
Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.
Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.
Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.
Major Breakthroughs in Treating Chronic Lymphocytic Leukemia
Susan M. O'Brien, MD, discusses breakthroughs in the treatment of chronic lymphocytic leukemia throughout the preceding year.
Second-Line Therapy for High-Risk Primary Myelofibrosis
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.
Second-Line Treatment Options for Myelofibrosis
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
Patient Case 1: Discussion
The panel continues their conversation about the first patient case.
Patient Case 1: A 65-Year-Old Man With RCC
Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.
Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer
Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.
Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy
An expert examines sequencing strategies for the treatment of metastatic prostate cancer.
Updated Safety Data and Treatment Selection in nmCRPC
Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.
Adverse Events with Next-Generation Androgen Receptor Inhibitors in nmCRPC
Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.
Unmet Needs and Future Directions
Zofia Piotrowska, MD, discusses unmet needs, novel treatment strategies and future perspectives for patients with EGFR exon 20-positive NSCLC.
Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC
Zofia Piotrowska, MD, shares insights on factors to consider when selecting the appropriate therapy for patients with EGFR exon 20-positive NSCLC.
Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC
Zofia Piotrowska, MD, evaluates the use of mobocertinib in patients with NSCLC and EGFR exon 20 insertions and provides updated results from key trials of mobocertinib in EGFR exon 20-positive NSCLC.
Role of PSMA PET Imaging in mCRPC
Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.
Assessing Treatment Response in Myelofibrosis
Monitoring patient response to frontline therapy for myelofibrosis, and circumstances for which a change in therapy may be appropriate.
Approaching a Case of Primary Myelofibrosis
Review of criteria used to assess and plan treatment for a 67-year-old patient with primary myelofibrosis.
Patient Case #2: Choosing Optimal Therapy in mCRPC
Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.
Presentation: Choosing Switch or Continuation Maintenance of Immune Checkpoint Inhibitors in Solid Tumors
Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.
